{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028161",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028161_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">aceclofenac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  aceclofenac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028161_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">aceclofenac</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  aceclofenac  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028161_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">aceclofenac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  aceclofenac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aceclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028162",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028162_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">Trimethoprim</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the anticoagulant effect of</ph> <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">acenocoumarol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Trimethoprim   is predicted to   increase   the anticoagulant effect of   acenocoumarol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028163",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028163_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"aciclovir\" outputclass=\"int-drug\">aciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  aciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028164",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028164_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"adefovir\" outputclass=\"int-drug\">adefovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  adefovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Adefovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028165",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028165_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  aliskiren  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aliskiren</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028166",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028166_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"amikacin\" outputclass=\"int-drug\">amikacin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  amikacin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amikacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028167",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028167_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  amiloride  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028167_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  amiloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028168",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028168_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">amitriptyline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  amitriptyline  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amitriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028169",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028169_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"amphotericin B\" outputclass=\"int-drug\">amphotericin B</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  amphotericin B  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amphotericin B</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028170",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028170_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">Trimethoprim</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of haematological toxicity when given with</ph> <ph otherprops=\"azathioprine\" outputclass=\"int-drug\">azathioprine</ph> <ph outputclass=\"int-substanceQualifier\">in renal transplant patients</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Trimethoprim   might   increase   the risk of haematological toxicity when given with   azathioprine   in renal transplant patients .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azathioprine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028171",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028171_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"azilsartan\" outputclass=\"int-drug\">azilsartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  azilsartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azilsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028172",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028172_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"bacitracin\" outputclass=\"int-drug\">bacitracin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  bacitracin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bacitracin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028173",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028173_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"bemiparin\" outputclass=\"int-drug\">bemiparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  bemiparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bemiparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028174",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028174_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  bendroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028175",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028175_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">bumetanide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  bumetanide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028176",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028176_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"candesartan\" outputclass=\"int-drug\">candesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  candesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Candesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028177",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028177_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"capreomycin\" outputclass=\"int-drug\">capreomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  capreomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Capreomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028178",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028178_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"captopril\" outputclass=\"int-drug\">captopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  captopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Captopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028179",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028179_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">carbamazepine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  carbamazepine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028180",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028180_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"carboplatin\" outputclass=\"int-drug\">carboplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  carboplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carboplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028181",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028181_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"cefaclor\" outputclass=\"int-drug\">cefaclor</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  cefaclor  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefaclor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028182",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028182_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"cefadroxil\" outputclass=\"int-drug\">cefadroxil</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  cefadroxil  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefadroxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028183",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028183_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"cefalexin\" outputclass=\"int-drug\">cefalexin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  cefalexin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefalexin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028184",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028184_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"cefazolin\" outputclass=\"int-drug\">cefazolin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  cefazolin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefazolin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028185",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028185_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"cefepime\" outputclass=\"int-drug\">cefepime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  cefepime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefepime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028186",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028186_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"cefixime\" outputclass=\"int-drug\">cefixime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  cefixime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefixime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028187",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028187_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"cefotaxime\" outputclass=\"int-drug\">cefotaxime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  cefotaxime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefotaxime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028188",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028188_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"cefoxitin\" outputclass=\"int-drug\">cefoxitin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  cefoxitin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefoxitin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028189",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028189_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"cefradine\" outputclass=\"int-drug\">cefradine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  cefradine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefradine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028190",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028190_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ceftaroline\" outputclass=\"int-drug\">ceftaroline</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  ceftaroline  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftaroline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028191",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028191_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ceftazidime\" outputclass=\"int-drug\">ceftazidime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  ceftazidime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftazidime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028192",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028192_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ceftobiprole\" outputclass=\"int-drug\">ceftobiprole</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  ceftobiprole  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftobiprole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028193",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028193_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ceftolozane\" outputclass=\"int-drug\">ceftolozane</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  ceftolozane  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftolozane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028194",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028194_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ceftriaxone\" outputclass=\"int-drug\">ceftriaxone</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  ceftriaxone  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftriaxone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028195",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028195_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"cefuroxime\" outputclass=\"int-drug\">cefuroxime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  cefuroxime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefuroxime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028196",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028196_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">celecoxib</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  celecoxib  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028196_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">celecoxib</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  celecoxib  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028196_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">celecoxib</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  celecoxib  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028197",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028197_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  chlorothiazide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028198",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028198_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  chlortalidone  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028199",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028199_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  ciclosporin  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028199_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  ciclosporin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028200",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028200_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"cidofovir\" outputclass=\"int-drug\">cidofovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  cidofovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cidofovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028201",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028201_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"cisplatin\" outputclass=\"int-drug\">cisplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  cisplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cisplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028202",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028202_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  citalopram  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028203",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028203_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  clomipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028204",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028204_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"colistimethate\" outputclass=\"int-drug\">Colistimethate</ph> <ph outputclass=\"int-substanceQualifier\">(particularly intravenous)</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of nephrotoxicity when given with</ph> <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Colistimethate   (particularly intravenous)   potentially   increases   the risk of nephrotoxicity when given with   trimethoprim .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Colistimethate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028205",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028205_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">dalteparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  dalteparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dalteparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028206",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028206_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  dapoxetine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028207",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028207_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dapsone\" outputclass=\"int-drug\">Dapsone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapsone\" outputclass=\"int-drug\">dapsone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dapsone   increases   the exposure to   trimethoprim  and  trimethoprim   increases   the exposure to   dapsone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapsone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028208",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028208_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-drug\">darbepoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  darbepoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darbepoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028209",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028209_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"desmopressin\" outputclass=\"int-drug\">desmopressin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  desmopressin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desmopressin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028210",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028210_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">dexketoprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  dexketoprofen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028210_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">dexketoprofen</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  dexketoprofen  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028210_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">dexketoprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  dexketoprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028211",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028211_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">diclofenac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  diclofenac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028211_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">diclofenac</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  diclofenac  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028211_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">diclofenac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  diclofenac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028212",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028212_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">Trimethoprim</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"digoxin\" outputclass=\"int-drug\">digoxin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor <ph otherprops=\"digoxin\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/digoxin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP752\">digoxin</xref></ph> concentration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Trimethoprim   increases   the concentration of   digoxin .  Manufacturer advises monitor  digoxin  concentration .    \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Digoxin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028213",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028213_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">dosulepin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  dosulepin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dosulepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028214",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028214_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"doxepin\" outputclass=\"int-drug\">doxepin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  doxepin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028215",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028215_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"drospirenone\" outputclass=\"int-drug\">drospirenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  drospirenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Drospirenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028216",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028216_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  duloxetine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028217",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028217_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"enalapril\" outputclass=\"int-drug\">enalapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  enalapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enalapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028218",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028218_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">enoxaparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  enoxaparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enoxaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028219",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028219_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  eplerenone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028219_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  eplerenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028220",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028220_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"epoetin alfa\" outputclass=\"int-drug\">epoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  epoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028221",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028221_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"epoetin beta\" outputclass=\"int-drug\">epoetin beta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  epoetin beta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin beta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028222",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028222_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"epoetin zeta\" outputclass=\"int-drug\">epoetin zeta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  epoetin zeta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin zeta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028223",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028223_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"eprosartan\" outputclass=\"int-drug\">eprosartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  eprosartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eprosartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028224",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028224_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  escitalopram  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028225",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028225_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"etodolac\" outputclass=\"int-drug\">etodolac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  etodolac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028225_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"etodolac\" outputclass=\"int-drug\">etodolac</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  etodolac  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028225_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"etodolac\" outputclass=\"int-drug\">etodolac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  etodolac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etodolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028226",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028226_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">etoricoxib</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  etoricoxib  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028226_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">etoricoxib</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  etoricoxib  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028226_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">etoricoxib</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  etoricoxib  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoricoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028227",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028227_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  fluoxetine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028228",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028228_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">flurbiprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  flurbiprofen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028228_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">flurbiprofen</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  flurbiprofen  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028228_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">flurbiprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  flurbiprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurbiprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028229",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028229_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  fluvoxamine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028230",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028230_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"foscarnet\" outputclass=\"int-drug\">foscarnet</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  foscarnet  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Foscarnet</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028231",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028231_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">Trimethoprim</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">fosphenytoin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor concentration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Trimethoprim   increases   the concentration of   fosphenytoin .  Manufacturer advises monitor concentration .    \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028232",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028232_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"furosemide\" outputclass=\"int-drug\">furosemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  furosemide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028233",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028233_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"gabapentin\" outputclass=\"int-drug\">gabapentin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  gabapentin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gabapentin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028234",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028234_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ganciclovir\" outputclass=\"int-drug\">ganciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  ganciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028235",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028235_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"gentamicin\" outputclass=\"int-drug\">gentamicin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  gentamicin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gentamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028236",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028236_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"heparin\" outputclass=\"int-drug\">heparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  heparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Heparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028237",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028237_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  hydrochlorothiazide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028238",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028238_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  hydroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028239",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028239_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">ibuprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  ibuprofen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028239_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">ibuprofen</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  ibuprofen  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028239_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">ibuprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  ibuprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028240",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028240_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ifosfamide\" outputclass=\"int-drug\">ifosfamide</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  ifosfamide  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ifosfamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028241",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028241_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"imidapril\" outputclass=\"int-drug\">imidapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  imidapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imidapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028242",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028242_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  imipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028243",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028243_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  indapamide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028244",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028244_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"indometacin\" outputclass=\"int-drug\">indometacin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  indometacin  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028244_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"indometacin\" outputclass=\"int-drug\">indometacin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  indometacin  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028244_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"indometacin\" outputclass=\"int-drug\">indometacin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  indometacin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indometacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028245",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028245_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"inotersen\" outputclass=\"int-drug\">inotersen</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  inotersen  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotersen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028246",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028246_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"irbesartan\" outputclass=\"int-drug\">irbesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  irbesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irbesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028247",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028247_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">ketoprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  ketoprofen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028247_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">ketoprofen</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  ketoprofen  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028247_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">ketoprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  ketoprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028248",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028248_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">ketorolac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  ketorolac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028248_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">ketorolac</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  ketorolac  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028248_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">ketorolac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  ketorolac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketorolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028249",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028249_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">Trimethoprim</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"lamivudine\" outputclass=\"int-drug\">lamivudine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Trimethoprim   slightly   increases   the exposure to   lamivudine .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lamivudine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028250",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028250_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"lisinopril\" outputclass=\"int-drug\">lisinopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  lisinopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028251",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028251_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"losartan\" outputclass=\"int-drug\">losartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  losartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Losartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028252",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028252_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">mefenamic acid</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  mefenamic acid  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028252_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">mefenamic acid</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  mefenamic acid  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028252_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">mefenamic acid</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  mefenamic acid  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028253",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028253_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">meloxicam</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  meloxicam  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028253_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">meloxicam</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  meloxicam  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028253_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">meloxicam</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  meloxicam  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meloxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028254",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028254_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">Trimethoprim</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of haematological toxicity when given with</ph> <ph otherprops=\"mercaptopurine\" outputclass=\"int-drug\">mercaptopurine</ph> <ph outputclass=\"int-substanceQualifier\">in renal transplant patients</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Trimethoprim   might   increase   the risk of haematological toxicity when given with   mercaptopurine   in renal transplant patients .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mercaptopurine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028255",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028255_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  methotrexate  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028255_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">Trimethoprim</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of adverse effects when given with</ph> <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Trimethoprim   increases   the risk of adverse effects when given with   methotrexate .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028256",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028256_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  metolazone  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028257",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028257_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">nabumetone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  nabumetone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028257_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">nabumetone</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  nabumetone  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028257_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">nabumetone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  nabumetone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabumetone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028258",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028258_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"naproxen\" outputclass=\"int-drug\">naproxen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  naproxen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028258_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"naproxen\" outputclass=\"int-drug\">naproxen</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  naproxen  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028258_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"naproxen\" outputclass=\"int-drug\">naproxen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  naproxen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naproxen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028259",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028259_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"neomycin\" outputclass=\"int-drug\">neomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  neomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Neomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028260",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028260_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">nortriptyline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  nortriptyline  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nortriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028261",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028261_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"olmesartan\" outputclass=\"int-drug\">olmesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  olmesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olmesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028262",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028262_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"oxaliplatin\" outputclass=\"int-drug\">oxaliplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  oxaliplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxaliplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028263",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028263_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">parecoxib</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  parecoxib  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028263_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">parecoxib</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  parecoxib  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028263_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">parecoxib</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  parecoxib  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Parecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028264",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028264_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  paroxetine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028265",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028265_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  pemetrexed  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pemetrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028266",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028266_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"penicillamine\" outputclass=\"int-drug\">penicillamine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  penicillamine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Penicillamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028267",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028267_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"pentamidine\" outputclass=\"int-drug\">pentamidine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  pentamidine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentamidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028268",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028268_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"perindopril\" outputclass=\"int-drug\">perindopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  perindopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perindopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028269",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028269_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"phenazone\" outputclass=\"int-drug\">phenazone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  phenazone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028269_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"phenazone\" outputclass=\"int-drug\">phenazone</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  phenazone  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028269_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"phenazone\" outputclass=\"int-drug\">phenazone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  phenazone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028270",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028270_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">Trimethoprim</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">phenytoin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor concentration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Trimethoprim   increases   the concentration of   phenytoin .  Manufacturer advises monitor concentration .    \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028271",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028271_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">piroxicam</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  piroxicam  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028271_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">piroxicam</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  piroxicam  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028271_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">piroxicam</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  piroxicam  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Piroxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028272",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028272_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"polymyxin b\" outputclass=\"int-drug\">polymyxin b</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  polymyxin b  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Polymyxin b</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028273",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028273_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"potassium aminobenzoate\" outputclass=\"int-drug\">potassium aminobenzoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  potassium aminobenzoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium aminobenzoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028274",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028274_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"potassium canrenoate\" outputclass=\"int-drug\">potassium canrenoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  potassium canrenoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium canrenoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028275",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028275_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"potassium chloride\" outputclass=\"int-drug\">potassium chloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  potassium chloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028276",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028276_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">Trimethoprim</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pramipexole\" outputclass=\"int-drug\">pramipexole</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Trimethoprim   is predicted to   increase   the exposure to   pramipexole .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pramipexole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028277",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028277_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"pyrimethamine\" outputclass=\"int-drug\">Pyrimethamine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of adverse effects when given with</ph> <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Pyrimethamine   increases   the risk of adverse effects when given with   trimethoprim .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pyrimethamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028278",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028278_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"quinapril\" outputclass=\"int-drug\">quinapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  quinapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028279",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028279_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"ramipril\" outputclass=\"int-drug\">ramipril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  ramipril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramipril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028280",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028280_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">Trimethoprim</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor blood glucose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Trimethoprim   slightly   increases   the exposure to   repaglinide .  Manufacturer advises avoid or monitor blood glucose .    \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Repaglinide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028281",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028281_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   decreases   the exposure to   trimethoprim .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028282",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028282_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">Trimethoprim</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"sapropterin\" outputclass=\"int-drug\">sapropterin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Trimethoprim   is predicted to   decrease   the efficacy of   sapropterin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sapropterin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028283",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028283_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  sertraline  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028284",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028284_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"sodium picosulfate\" outputclass=\"int-drug\">sodium picosulfate</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  sodium picosulfate  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium picosulfate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028285",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028285_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  spironolactone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028285_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  spironolactone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Spironolactone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028286",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028286_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"streptomycin\" outputclass=\"int-drug\">streptomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  streptomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028287",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028287_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"streptozocin\" outputclass=\"int-drug\">streptozocin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  streptozocin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptozocin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028288",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028288_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"sulindac\" outputclass=\"int-drug\">sulindac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  sulindac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028288_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"sulindac\" outputclass=\"int-drug\">sulindac</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  sulindac  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028288_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"sulindac\" outputclass=\"int-drug\">sulindac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  sulindac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulindac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028289",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028289_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  tacrolimus  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028289_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  tacrolimus  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tacrolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028290",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028290_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"telmisartan\" outputclass=\"int-drug\">telmisartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  telmisartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telmisartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028291",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028291_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tenofovir disoproxil\" outputclass=\"int-drug\">tenofovir disoproxil</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  tenofovir disoproxil  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenofovir disoproxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028292",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028292_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">tenoxicam</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  tenoxicam  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028292_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">tenoxicam</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  tenoxicam  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028292_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">tenoxicam</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  tenoxicam  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenoxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028293",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028293_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">tiaprofenic acid</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  tiaprofenic acid  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028293_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">tiaprofenic acid</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  tiaprofenic acid  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028293_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">tiaprofenic acid</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  tiaprofenic acid  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tiaprofenic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028294",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028294_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">tinzaparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  tinzaparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tinzaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028295",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028295_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tobramycin\" outputclass=\"int-drug\">tobramycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  tobramycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tobramycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028296",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028296_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">tolfenamic acid</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  tolfenamic acid  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028296_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">tolfenamic acid</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  tolfenamic acid  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028296_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">tolfenamic acid</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  trimethoprim  and  tolfenamic acid  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolfenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028297",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028297_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"tolvaptan\" outputclass=\"int-drug\">tolvaptan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  tolvaptan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolvaptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028298",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028298_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"torasemide\" outputclass=\"int-drug\">torasemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  torasemide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028299",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028299_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"trandolapril\" outputclass=\"int-drug\">trandolapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  trandolapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trandolapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028300",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028300_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">Trimethoprim</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"treprostinil\" outputclass=\"int-drug\">treprostinil</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Trimethoprim   is predicted to   increase   the exposure to   treprostinil .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treprostinil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028301",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028301_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  triamterene  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028301_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  trimethoprim  and  triamterene  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamterene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028302",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028302_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">trimipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  trimipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028303",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028303_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"valaciclovir\" outputclass=\"int-drug\">valaciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  valaciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valaciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028304",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028304_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"valganciclovir\" outputclass=\"int-drug\">valganciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  valganciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028305",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028305_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"valsartan\" outputclass=\"int-drug\">valsartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  valsartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028306",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028306_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"vancomycin\" outputclass=\"int-drug\">vancomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  vancomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vancomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028307",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028307_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">Trimethoprim</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the anticoagulant effect of</ph> <ph otherprops=\"warfarin\" outputclass=\"int-drug\">warfarin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Trimethoprim   is predicted to   increase   the anticoagulant effect of   warfarin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028308",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028308_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  xipamide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028309",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028309_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"zidovudine\" outputclass=\"int-drug\">zidovudine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  zidovudine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zidovudine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028310",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2#bnf_i1643858028310_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"trimethoprim\" outputclass=\"int-heading-drug\">trimethoprim</ph> and <ph otherprops=\"zoledronate\" outputclass=\"int-drug\">zoledronate</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  trimethoprim  and  zoledronate  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zoledronate</title>"
					}
				}
			],
			"hasSearchLabel": " Trimethoprim  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/trimethoprim-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Trimethoprim </title>"
			},
			"rdfs:label": "trimethoprim"
		}
	]
}